Navigation Links
Intarcia Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality
Date:8/5/2014

ers."

About ITCA 650

ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted sub-dermally to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the duration and severity of GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031. ITCA 650 is currently in a global phase 3 clinical trial program called FREEDOM, and some of the first available phase 3 results were reported at the JP Morgan conference in January of this year and viewed as very promising. Top-line results from the FREEDOM 1 and HBL phase 3 studies will be reported in September and/or October of this year. Further results will be reported later in 2014 and 2015.

About Intarcia Therapeutics, Inc.

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy,
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
6. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
7. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
8. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
9. WuXi PharmaTech Announces Third-Quarter 2011 Results
10. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
11. Spherix Announces Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 30, 2014 Two ... America were hosted by Charm Sciences at its ... their week in the US, the participants discussed ... control, hygiene management, and process verification, and received ... , This was the first visit to the ...
(Date:10/31/2014)... October 31, 2014 Following the successful ... free learning webinar to introduce its new product and ... and biostatisticians. , Launched in September, Formedix On Demand ... of clinical trial automation tools. For the first time, ... browser. And by introducing Formations – a revolutionary new ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
Breaking Biology Technology:Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3
... ST PETER PORT, Guernsey and LONDON, July 6 ... to Drive Novel Antibiotics Platform Addressing,Areas of Major Unmet Need, ... Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor ... ("CP2"), today announces its,investment in a majority shareholding in Novacta ...
... NEW BRUNSWICK, N.J., July 3 Johnson & Johnson (NYSE: ... its tender offer for all outstanding shares of common stock of ... (Eastern time) on July 2, 2009. The offer was conducted ... Merger Sub, Inc. , , The depositary for the tender ...
... , PHOENIX, July 2 As many as ... with an eating disorder because they,re ashamed to admit they ... Eating and Anxiety Disorders . Healthcare professionals, family members ... in males that may signify an eating disorder. Therefore, effective ...
Cached Biology Technology:Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 2Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 3Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 4Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 5Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 2Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 3Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 4Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 2
(Date:10/31/2014)... good for attracting species, but it may not be enough ... study has found. , The researchers surveyed two types of ... abundance of two insects that interact with them. They found ... and black walnut, they didn,t find a corresponding abundance of ... the walnuts and black cherries and a type of wasp ...
(Date:10/31/2014)... 30, 2014  HITLAB SM , a healthcare ... its inaugural HITLAB Innovators Summit SM on ... HITLAB will partner with the Clinton Foundation,s Health ... ProtoHack, Columbia Business School Alumni Club of ... Engineering and Operations Research, bringing together leaders in ...
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2
... Institute of Nanoscience have discovered how to use the ... a chip. Based on this, they built a transport ... individually. To demonstrate this, the Delft researchers sorted the ... the University of Florida has called the Delft discovery ...
... working at the University of Bristol has found a ... food poisoning. Their work is reported in Nature Medicine. ... shown that one particular antibiotic ? fosfomycin ?can treat ... laboratory conditions. , Because it was not effective in ...
... Wegener Institute for Polar and Marine Research observed ... began in Ny-Ålesund on Svalbard. Monitoring instruments displayed ... found. Aerosols from eastern Europe have been transported ... large-scale weather situation. , Usually the air ...
Cached Biology News:Biological motors sort molecules one by one on a chip 2Record air pollution above the Arctic 2